marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-06-2024
Solid Biosciences Balance Sheet 2011-2024 | SLDB
Annual Balance Sheet Solid Biosciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-70.9 M | -152 M | -118 M | - | -69 M | -85.3 M | -52.1 M | -7.68 M | -28.6 M | - | - | - | - |
Long Term Debt |
1.23 M | 1.7 M | 275 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.86 M | 1.9 M | 1.26 M | 2 M | 1.74 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 5.15 M | 1.93 M | 124 M | 71.6 M | 61.7 M | - | - | - | - |
Total Current Liabilities |
14.5 M | 22.5 M | 23.6 M | 24.5 M | 18.3 M | 12.5 M | - | - | - | - | - | - | - |
Total Liabilities |
38.5 M | 48.6 M | 24.2 M | 39.1 M | 23.4 M | 14.4 M | 135 M | 78.5 M | 75.6 M | - | - | - | - |
Deferred Revenue |
- | - | - | 10.4 M | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-659 M | -563 M | -477 M | -405 M | -316 M | -199 M | -124 M | -84.9 M | -67.7 M | - | - | - | - |
Total Assets |
165 M | 260 M | 232 M | 171 M | 103 M | 140 M | 76.2 M | 40.6 M | 55.7 M | - | - | - | - |
Cash and Cash Equivalents |
74 M | 155 M | 119 M | 155 M | 76 M | 86.4 M | 52.1 M | 7.84 M | - | - | - | - | - |
Book Value |
126 M | 212 M | 208 M | 132 M | 80 M | 125 M | -59.3 M | -37.9 M | -19.9 M | - | - | - | - |
Total Shareholders Equity |
126 M | 212 M | 208 M | 132 M | 80 M | 125 M | -59.3 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Solid Biosciences
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
307 K | 953 K | 1.1 M | 1.23 M | 23.2 M | 23.6 M | 23.9 M | 24.3 M | - | 24.5 M | 231 K | 293 K | 353 K | 412 K | 469 K | 525 K | 525 K | 525 K | 525 K | 733 K | 733 K | 733 K | 733 K | 859 K | 859 K | 859 K | 859 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
22 M | 23 M | - | 23.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
44.8 M | 37.7 M | 38 M | 38.5 M | 40.4 M | 41 M | 45.8 M | 48.6 M | 41.2 M | 46.3 M | 22 M | 24.2 M | 25.6 M | 27.9 M | 32.3 M | 39.1 M | 39.1 M | 39.1 M | 39.1 M | 23.4 M | 23.4 M | 23.4 M | 23.4 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | 6.17 M | 8.08 M | 8.86 M | 10 M | 10.7 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-741 M | -708 M | -683 M | -659 M | -638 M | -617 M | -593 M | -563 M | -548 M | -527 M | -502 M | -477 M | -458 M | -440 M | -421 M | -405 M | -405 M | -405 M | -405 M | -316 M | -316 M | -316 M | -316 M | -199 M | -199 M | -199 M | -199 M | -124 M | -124 M | -124 M | -124 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
212 M | 231 M | 249 M | 165 M | 185 M | 205 M | 230 M | 260 M | 184 M | 208 M | 208 M | 232 M | 249 M | 266 M | 285 M | 171 M | 171 M | 171 M | 171 M | 103 M | 103 M | 103 M | 103 M | 140 M | 140 M | 140 M | 140 M | 76.2 M | 76.2 M | 76.2 M | 76.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
64.4 M | 95.9 M | 118 M | 74 M | 49 M | 91.6 M | 165 M | 155 M | 48.8 M | 54.3 M | 130 M | 119 M | 110 M | 201 M | 268 M | 155 M | 155 M | 155 M | 155 M | 76 M | 76 M | 76 M | 76 M | 86.4 M | 86.4 M | 86.4 M | 86.4 M | 52.1 M | 52.1 M | 52.1 M | 52.1 M | 7.68 M | - | - | - | 28.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
167 M | 193 M | 211 M | 126 M | 144 M | 164 M | 184 M | 212 M | 143 M | 162 M | 186 M | 208 M | 223 M | 238 M | 253 M | 132 M | 132 M | 132 M | 132 M | 80 M | 80 M | 80 M | 80 M | 125 M | 125 M | 125 M | 125 M | 64.9 M | 64.9 M | 64.9 M | 64.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
167 M | 193 M | 211 M | 126 M | 144 M | 164 M | 184 M | 212 M | 143 M | 162 M | 186 M | 208 M | 223 M | 238 M | 253 M | 132 M | 132 M | 132 M | 132 M | 80 M | 80 M | 80 M | 80 M | 125 M | 125 M | 125 M | 125 M | -59.3 M | -59.3 M | -59.3 M | -59.3 M | -37.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency